Pfizer names Albert Bourla group president
This article was originally published in Scrip
Pfizer has named Albert Bourla group president of the vaccines, oncology and consumer healthcare business, effective 1 January 2014. He replaces Amy Schulman (www.scripintelligence.com, 17 December 2013), who was due to take up the position when the company began operating under its new three-armed commercial business structure in January 2014. Ms Schulman is stepping down from the company entirely but will remain for a transitional period. Meanwhile, Susan Silbermann has been named president and general manager, of Pfizer's global vaccines business – also effective 1 January 2014.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.